Synergistic Bladder Cancer Treatment System

A comprehensive system integrating antigen presenting cells, IL-15 based superagonists, and cutting-edge technologies like blockchain, AI, and IoT to revolutionize bladder cancer treatment by enhancing immune response, monitoring patient outcomes, and predicting treatment efficacy.

The original patent disclosed a vaccine composition for treating bladder cancer using antigen presenting cells and IL-15 based superagonists. However, it lacked a comprehensive system for tracking patient response, predicting treatment outcomes, and optimizing the immune response. The new inventive concept addresses these limitations by synergistically combining the patented vaccine composition with advanced technologies to create a more powerful and effective treatment system.

The Synergistic Bladder Cancer Treatment System consists of a composition including antigen presenting cells isolated from a subject treated with Bacillus Calmette-Guerin (BCG) and cultured with IL-15 based superagonists. This composition is integrated with a blockchain-based tracking module for monitoring patient response to the composition, ensuring secure and transparent data management. Additionally, the system incorporates artificial intelligence (AI) to predict and optimize the immune response, and a sensor-enabled device for monitoring the patient's immune response and transmitting data to a cloud-based server for analysis. The system also includes a machine learning algorithm trained on data from patients treated with the composition, enabling the prediction of patient response to bladder cancer treatment.

The new claims introduce the innovative combination of the patented vaccine composition with blockchain, AI, IoT, and machine learning technologies, providing a novel and non-obvious solution for treating bladder cancer. The integration of these technologies enables a more effective and personalized treatment approach, overcoming the limitations of the original patent.

Alternative embodiments of the Synergistic Bladder Cancer Treatment System could include the use of different types of antigen presenting cells, varying IL-15 based superagonist formulations, or the integration of other advanced technologies like nanotechnology or gene editing. These variations would ensure broad conceptual coverage and adaptability to different treatment scenarios.

The Synergistic Bladder Cancer Treatment System has significant commercial potential in the oncology market, particularly in the treatment of bladder cancer. The system's ability to enhance immune response, monitor patient outcomes, and predict treatment efficacy could lead to improved patient survival rates, reduced healthcare costs, and increased market share for NantCell, Inc.